Description     Claims  

US3979399A   [0002] 
US3840546A   [0002] 
US3966746A   [0002] 
US3925388A   [0003] 
US3856799A   [0003] 
US3833594A   [0003] 
US3755340A   [0003] 
CA1003419   [0005] 
CH553799   [0005] 
US3833598A   [0006] 
GB1417489A   [0006] 
US4115394A   [0007] 
GB1511006A   [0007] 
JP2002020386A   [0008]  [0008] 
EP0076035A1   [0009] 
WO02060900A2   [0011] 
WO02060900A   [0011] 
WO0015222A   [0014] 
GB2242134A   [0246]  [0267] 
WO0012078A   [0254] 
WO02066422A   [0255]  [0256]  [0257] 
WO03024439A   [0255]  [0258] 
WO02070490A   [0255] 
WO02076933A   [0255] 
WO03011274A2   [0260] 
WO02069945A2   [0260] 
US20020193393A1   [0260] 
US2002052312A1   [0260] 
EP418716A1   [0260] 
WO9313055A   [0262] 
WO9830537A   [0262] 
WO0250021A   [0262] 
WO9534534A   [0262] 
WO9962875A   [0262] 
WO0226722A   [0262] 
US4335121A   [0263] 
WO0212266A1   [0263]  [0263] 
WO03030939A1   [0264]  [0264] 
EP0300598W   [0267] 
WO03061743A1   [0267] 
WO9420079A   [0271] 
EP50407A   [0348] 
WO00032565A   [0350] 
WO0042011A   [0383] 
DE3618142   [0385] 
WO9907702A   [0447] 
DE10008089   [0464] 
WO03082190A   [0464] 
WO03022835A   [0485] 
WO9305772A   [0485] 
WO02085860A   [0487] 
WO02102799A   [0489] 
US4895860A   [0502] 
WO00006159A   [0505] 
EP323864A   [0515] 
US4219660A   [0548] 
WO9912933A   [0548] 
EP1188744A   [0548] 
WO02016318A   [0684] 
WO9605166A   [0684] 

J. Heterocycl. Chem.   [0004] 
Archiv der Pharmazie   [0005] 
Med. Chem. Res.   [0010] 
Drug Development Research   [0010] 
Bioorg. Med. Chem. Lett.   [0010] 
J. Med. Chem.   [0010] 
Indian J. Chem.   [0012] 
Synthetic Commun   [0013] 
J. Med Chem.   [0159]  [0160] 
J. Med Chem.   [0162]  [0336] 
J. Chem. Soc., Perkin Trans.   [0163] 
Tetrahedron   [0176] 
Tetrahedron   [0176] 
J. Org. Chem.   [0192] 
Drugs   [0205] 
Current Opinion in Chemical Biology   [0205]  [0206]  [0285] 
Expert Opinion on Investigational Drugs   [0205]  [0206]  [0208] 
Current Pharmaceutical Design   [0205] 
Current Opinion Chem. Biol   [0205] 
Emerging Drugs   [0206] 
Current Pharmaceutical Design   [0206] 
Current Opinion Chem. Biol.   [0206]  [0208]  [0208] 
Emerging Drugs   [0206] 
J. Allergy & Clinical Immunology   [0207] 
Cun-ent Pharmaceutical Design   [0208] 
Indian J. Exp. Biol.   [0209] 
Psychopharmacology   [0210] 
Neuropsychopharmacology   [0210] 
Japanese J. Pharmacol.   [0210] 
CNS Drug Reviews   [0211] 
Expert Opinion on Investigational Drugs   [0211] 
Neuropsychopharmacology   [0211] 
A low Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain: cloning and expression of cDNA, biochemical characterisation of recombinant protein, and tissue distribution of mRNA   [0271] 
Isolation of a cDNA encoding a human rolipram-sensitive cyclic AMP phoshodiesterase (PDE IVD)   [0272] 
Isolation and characterisation of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase   [0273] 
Characterisation of a novel potent and specific inhibitor of type V phosphodiesterase   [0274] 
Activation and solubilization of the retinal cGMP-specific phosphodiesterase by limited proteolysis   [0275] 
Purification of bovine retinal cGMP phosphodiesterase   [0275] 
Effects of magnesium on cyclic GMP hydrolysis by the bovine retinal rod cyclic GMP phosphodiesterase   [0275] 
Emesis induced by inhibitors of [PDE IV] in the ferret   [0285] 
Neuropharmacology   [0285] 
Chest.   [0288] 
Comparison of the structural and inflammatory features of COPD and asthma   [0292] 
Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 and 4 in brown Norway rats   [0293] 
Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (Ariflo™), in a rat model of pulmonary neutrophilia   [0294] 
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung   [0295] 
Multiple cyclic nucleotide phosphodiesterases   [0304] 
Comparison of PDE 4 inhibitors, Rolipram and SB 207499 (Ariflo™), in a rat model of pulmonary neutrophilia   [0305] 
Pica in rats is analogous to emesis: an animal model in emesis research   [0306] 
Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats   [0307] 
Neuropharmacological mechanisms of emesis. II . Effects of antiemetic drugs on cisplatin-induced pica in rats   [0308] 
J. Molecular Structure   [0395] 
Organic Process Research and Development   [0433] 
Anales Die Quimica   [0443] 
J. Amer. Chem. Soc.   [0449] 
J. Org. Chem.   [0464] 
J. Med. Chem.   [0464] 
Synthesis   [0464] 
Eur. J. Med. Chem.   [0464] 
Indian J. Chemistry   [0464] 
J. Med. Chem.   [0466] 
Chem Pharm Bull   [0481] 
J. Chem. Soc., Perkin Trans II   [0485] 
J. Am. Chem. Soc   [0500] 
Bull. Chem. Soc. Jpn.   [0511] 
A1 European J.Med Chem.   [0519] 
Collect. Czech. Chem. Commun   [0521] 
Bioorganic Medicinal Chemistry Letters   [0523] 
J. Org. Chem.   [0540] 
Tetrahedron   [0541] 
Arch. Pharm.   [0541] 
J. Org. Chem.   [0543] 
J. Org. Chem.   [0543] 
J. Am. Chem. Soc.   [0543] 
J. Chem. Soc., Perkin Trans. 1   [0548] 
J. Chem. Soc., Perkin. Trans 1   [0548] 
J. Org. Chem.   [0548] 
J. Med. Chem.   [0548] 
J. Med. Chem.   [0574] 
J.Med.Chem.   [0684] 
J.Med.Chem.   [0684]